<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD v1.1 20151215//EN" "JATS-archivearticle1.dtd"> 
<article xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" open-status="O" article-type="research-article"><?properties open_access?><?DTDIdentifier.IdentifierValue -//NLM//DTD JATS (Z39.96) Journal Publishing DTD v1.1 20151215//EN?><?DTDIdentifier.IdentifierType public?><?SourceDTD.DTDName JATS-journalpublishing1.dtd?><?SourceDTD.Version 1.1?><?ConverterInfo.XSLTName jp2nlmx2.xsl?><?ConverterInfo.Version 1?><front><journal-meta><journal-id journal-id-type="nlm-ta">Gen Psychiatr</journal-id><journal-id journal-id-type="iso-abbrev">Gen Psychiatr</journal-id><journal-id journal-id-type="hwp">gpsych</journal-id><journal-id journal-id-type="publisher-id">gpsych</journal-id><journal-title-group><journal-title>General Psychiatry</journal-title></journal-title-group><issn pub-type="epub">2517-729X</issn><publisher><publisher-name>BMJ Publishing Group</publisher-name><publisher-loc>BMA House, Tavistock Square, London, WC1H 9JR</publisher-loc></publisher></journal-meta><article-meta><article-id pub-id-type="pmcid">6371651</article-id><article-id pub-id-type="publisher-id">gpsych-2018-100018</article-id><article-id pub-id-type="doi">10.1136/gpsych-2018-100018</article-id><article-categories><subj-group subj-group-type="heading"><subject>Original Article</subject></subj-group><subj-group subj-group-type="hwp-journal-coll"><subject>1506</subject></subj-group></article-categories><title-group><article-title><SecTag type="TITLE"><text><SENT sid="90455" pm="."><plain>Increased plasma leptin as a novel predictor for psychopathological depressive symptoms in chronic schizophrenia </plain></SENT>
</text></SecTag></article-title></title-group><contrib-group><contrib id="author-65269645" contrib-type="author" equal-contrib="yes"><name><surname>Xu</surname><given-names>Jinjie</given-names></name><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="aff" rid="aff2">2</xref><xref ref-type="aff" rid="aff3">3</xref><xref ref-type="bio" rid="d35e44">*</xref></contrib><contrib id="author-65269610" contrib-type="author" equal-contrib="yes"><name><surname>Jiao</surname><given-names>Yumei</given-names></name><xref ref-type="aff" rid="aff1">1</xref></contrib><contrib id="author-65269674" contrib-type="author"><name><surname>Xing</surname><given-names>Mengjuan</given-names></name><xref ref-type="aff" rid="aff1">1</xref></contrib><contrib id="author-65269738" contrib-type="author"><name><surname>Lin</surname><given-names>Yezhe</given-names></name><xref ref-type="aff" rid="aff1">1</xref></contrib><contrib id="author-65269760" contrib-type="author"><name><surname>Su</surname><given-names>Yousong</given-names></name><xref ref-type="aff" rid="aff1">1</xref></contrib><contrib id="author-65269775" contrib-type="author"><name><surname>Ding</surname><given-names>Wenhua</given-names></name><xref ref-type="aff" rid="aff1">1</xref></contrib><contrib id="author-65269788" contrib-type="author"><name><surname>Zhu</surname><given-names>Cuizhen</given-names></name><xref ref-type="aff" rid="aff1">1</xref></contrib><contrib id="author-65269798" contrib-type="author"><name><surname>Peng</surname><given-names>Yanmin</given-names></name><xref ref-type="aff" rid="aff1">1</xref></contrib><contrib id="author-65269865" contrib-type="author"><name><surname>Qi</surname><given-names>Dake</given-names></name><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="aff" rid="aff4">4</xref></contrib><contrib id="author-65269454" contrib-type="author" corresp="yes"><name><surname>Cui</surname><given-names>Donghong</given-names></name><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="aff" rid="aff2">2</xref><xref ref-type="aff" rid="aff5">5</xref></contrib></contrib-group><aff id="aff1">
<label>1</label>
<institution content-type="department">Shanghai Mental Health Center</institution>, <institution>Shanghai Jiao Tong University, School of Medicine</institution>, <addr-line content-type="city">Shanghai</addr-line>, <country>China</country>
</aff><aff id="aff2">
<label>2</label>
<institution>Shanghai Key Laboratory of Psychotic Disorders</institution>, <addr-line content-type="city">Shanghai</addr-line>, <country>China</country>
</aff><aff id="aff3">
<label>3</label>
<institution content-type="department">Beijing Anding Hospital</institution>, <institution>Capital Medical University</institution>, <addr-line content-type="city">Beijing</addr-line>, <country>China</country>
</aff><aff id="aff4">
<label>4</label>
<institution content-type="department">Division of Biomedical Sciences, Faculty of Medicine</institution>, <institution>Memorial University of Newfoundland</institution>, <addr-line content-type="city">St. John’s</addr-line>, <addr-line content-type="state">Newfoundland and Labrador</addr-line>, <country>Canada</country>
</aff><aff id="aff5">
<label>5</label>
<institution content-type="department">Brain Science and Technology Research Center</institution>, <institution>Shanghai Jiao Tong University</institution>, <addr-line content-type="city">Shanghai</addr-line>, <country>China</country>
</aff><author-notes><corresp><label>Correspondence to</label> Dr Donghong Cui; <email>manyucc@126.com</email></corresp></author-notes><pub-date pub-type="collection"><year>2018</year></pub-date><pub-date pub-type="epub"><day>19</day><month>12</month><year>2018</year></pub-date><volume>31</volume><issue>3</issue><elocation-id>e100018</elocation-id><history><date date-type="received"><day>24</day><month>9</month><year>2018</year></date><date date-type="rev-recd"><day>16</day><month>11</month><year>2018</year></date><date date-type="accepted"><day>18</day><month>11</month><year>2018</year></date></history><permissions><copyright-statement>© Author(s) (or their employer(s)) 2018. Re-use permitted under CC BY-NC. No commercial re-use. See rights and permissions. Published by BMJ.</copyright-statement><copyright-year>2018</copyright-year><license license-type="open-access"><license-p>This is an Open Access article distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: <ext-link ext-link-type="uri" xlink:href="http://creativecommons.org/licenses/by-nc/4.0">http://creativecommons.org/licenses/by-nc/4.0</ext-link></license-p></license></permissions><self-uri xlink:title="pdf" xlink:href="gpsych-2018-100018.pdf"/><abstract><sec><title><text><SENT sid="90456" pm="."><plain>Background </plain></SENT>
</text></title><p><SecTag type="ABS"><text><SENT sid="90457" pm="."><plain>Depressive symptoms are often seen in schizophrenia. </plain></SENT>
<SENT sid="90458" pm="."><plain>The overlap in presentation makes it difficult to distinguish depressive symptoms from the negative symptoms of schizophrenia. </plain></SENT>
<SENT sid="90459" pm="."><plain>The adipokine leptin was found to be altered in both depression and schizophrenia. </plain></SENT>
<SENT sid="90460" pm="."><plain>There are few studies focusing on the prediction of leptin in diagnosis and evaluation of depressive symptoms in schizophrenia. </plain></SENT>
</text></SecTag></p></sec><sec><title><text><SENT sid="90461" pm="."><plain>ObjectiveAims </plain></SENT>
</text></title><p><SecTag type="ABS"><text><SENT sid="90462" pm="."><plain>To assess the plasma leptin level in patients with schizophrenia and its relationships with depressive symptoms. </plain></SENT>
</text></SecTag></p></sec><sec><title><text><SENT sid="90463" pm="."><plain>Methods </plain></SENT>
</text></title><p><SecTag type="ABS"><text><SENT sid="90464" pm="."><plain>Cross-sectional studies were applied to (1) compare the levels of plasma leptin between schizophrenia (n=74) and healthy controls (n=50); and (2) investigate the relationship between plasma leptin levels and depressive subscores. </plain></SENT>
</text></SecTag></p></sec><sec><title><text><SENT sid="90465" pm="."><plain>Results </plain></SENT>
</text></title><p><SecTag type="ABS"><text><SENT sid="90466" pm="."><plain>(1) Plasma leptin levels were significantly higher in patients with schizophrenia than in healthy controls. </plain></SENT>
<SENT sid="90467" pm="."><plain>(2) Correlation analysis revealed a significant negative association between leptin levels and the depressed factor scores on the Positive and Negative Syndrome Scale (PANSS). </plain></SENT>
<SENT sid="90468" pm="."><plain>(3) Stepwise multiple regression analyses identified leptin as an influencing factor for depressed factor score on PANSS. </plain></SENT>
</text></SecTag></p></sec><sec><title><text><SENT sid="90469" pm="."><plain>Conclusion </plain></SENT>
</text></title><p><SecTag type="ABS"><text><SENT sid="90470" pm="."><plain>Leptin may serve as a predictor for the depressive symptoms of chronic schizophrenia. </plain></SENT>
</text></SecTag></p></sec></abstract><SecTag type="KEYWORD"><kwd-group><kwd>leptin</kwd><kwd>depressive symptoms</kwd><kwd>chronic schizophrenia</kwd></kwd-group></SecTag><funding-group><award-group id="funding-1"><funding-source><institution-wrap><institution>Canadian Institutes of Health Research Project Grant</institution></institution-wrap></funding-source><award-id>PJT-156116</award-id></award-group><award-group id="funding-2"><funding-source><institution-wrap><institution>National Key R&amp;D Program of China</institution></institution-wrap></funding-source><award-id>2017YFC0909200</award-id></award-group><award-group id="funding-3"><funding-source><institution-wrap><institution>National Science Foundation of China</institution></institution-wrap></funding-source><award-id>NSFC81171266</award-id><award-id>NSFC81271481</award-id><award-id>NSFC81500976</award-id><award-id>NSFC81671336</award-id></award-group><award-group id="funding-4"><funding-source><institution-wrap><institution>Shanghai Key Laboratory of Psychotic Disorders</institution></institution-wrap></funding-source><award-id>13dz2260500</award-id></award-group><award-group id="funding-5"><funding-source><institution-wrap><institution>Shanghai Municipal Planning Commission of Science and Research Fund</institution></institution-wrap></funding-source><award-id>20154Y0194</award-id></award-group><award-group id="funding-6"><funding-source><institution-wrap><institution>China and National Key Research and Development Program</institution></institution-wrap></funding-source><award-id>2017YFC0909200</award-id></award-group></funding-group><custom-meta-group><custom-meta><meta-name>special-feature</meta-name><meta-value>unlocked</meta-value></custom-meta></custom-meta-group></article-meta></front><body><SecTag type="INTRO"><sec sec-type="intro" id="s1"><title><text><SENT sid="90471" pm="."><plain>Introduction </plain></SENT>
</text></title><p><text><SENT sid="90472" pm="."><plain>Schizophrenia is a chronic and severe mental disorder with a lifetime prevalence of around 1% globally.1 It has a profound impact on individuals, families and society. </plain></SENT>
<SENT sid="90473" pm="."><plain>Over half of the patients with schizophrenia suffer from intermittent psychosis and approximately one-fifth of them have chronic symptoms, and mental and physical disability.2 Schizophrenia is characterised by diverse psychopathology with symptoms that are commonly divided into five dimensions: positive symptoms, negative symptoms, cognitive symptoms, aggressive symptoms and affective symptoms.3 Depressive symptoms (seen as one end on the spectrum of affective symptoms) frequently accompany schizophrenia, may be part of the prodromal symptomology, following an acute episode, or occur between psychotic episodes.4 Although not as dramatic as positive and aggressive symptoms, it should be noted that the depressive symptoms of schizophrenia have been reported to be associated with various less favourable outcomes in schizophrenia.5–7 These include poorer responses to medication, greater impairments in social and vocational functioning, more personal stigma, higher risk of discontinuation of medication and rehospitalisation, longer durations of hospitalisation, greater family and societal burden, more negative life events and even increased rate of suicide attempts and completed suicides.8–10 Unfortunately, less attention is paid to depressive symptoms than other symptom domains of schizophrenia. </plain></SENT>
<SENT sid="90474" pm="."><plain>To make matters worse, it is quite difficult to distinguish a depressive syndrome from other diagnoses with overlapping features, in particular the negative symptoms commonly seen in schizophrenia. </plain></SENT>
<SENT sid="90475" pm="."><plain>The negative syndrome includes a number of clinical presentations which are similar to components of the depression syndrome, such as anhedonia, anergia, alogia, blunted affect, social withdrawal and loss of motivation, which may confuse doctors.11 12 Accordingly, patients may not receive adjunctive antidepressant treatment in good time. </plain></SENT>
<SENT sid="90476" pm="."><plain>Therefore, a biomarker for depressive syndromes is of great interest. </plain></SENT>
</text></p><p><text><SENT sid="90477" pm="."><plain>Leptin, encoded by the obese (ob﻿) gene, is a 16 kD protein primarily synthesised and secreted by adipocytes. </plain></SENT>
<SENT sid="90478" pm="."><plain>It exerts multiple biological functions by binding to its receptors. </plain></SENT>
<SENT sid="90479" pm="."><plain>Initially, leptin was found to inhibit food intake and promote energy consumption and therefore it was known as an antiobesity hormone.13 However, the function of leptin has recently been broadened into involvement of mood disorders, in particular depression.14–17 Ample literature has indicated leptin as a novel modulator of depressive mood. </plain></SENT>
<SENT sid="90480" pm="."><plain>Animal studies showed that leptin receptors were highly expressed in mood-related brain regions including the amygdala, cortex and hippocampus.18 Clinical studies found decreased leptin levels in patients with major depression and observed increases in leptin levels accompanied with improvements in depressive symptoms following antidepressant treatment.19–22 Therefore, plasma leptin may serve as a peripheral biomarker for the differential diagnosis and evaluation of depressive syndromes in schizophrenia. </plain></SENT>
</text></p><p><text><SENT sid="90481" pm="."><plain>In light of the findings mentioned above, we hypothesised that the plasma leptin levels may be associated with depressive symptoms in chronic schizophrenia. </plain></SENT>
<SENT sid="90482" pm="."><plain>Therefore, our present study aims to investigate (1) whether plasma leptin levels were altered in patients with schizophrenia; (2) whether there was a relationship between plasma leptin levels and psychopathological parameters, particularly the depressive subscore. </plain></SENT>
</text></p></sec></SecTag><SecTag type="METHODS"><sec sec-type="methods" id="s2"><title><text><SENT sid="90483" pm="."><plain>Methods </plain></SENT>
</text></title><sec id="s2-1"><title><text><SENT sid="90484" pm="."><plain>Subjects </plain></SENT>
</text></title><p><text><SENT sid="90485" pm="."><plain>Eighty-five inpatients were recruited from January 2017 to June 2017, and 52 healthy controls matched for gender, age and body mass index (BMI) were recruited by advertisement (figure 1). </plain></SENT>
</text></p><SecTag type="FIG"><fig id="F1" orientation="portrait" position="float"><label>Figure 1</label><caption><p><text><SENT sid="90486" pm="."><plain>The flow chart of the study. </plain></SENT>
</text></p></caption><graphic xlink:href="gpsych-2018-100018f01"/></fig></SecTag><p><text><SENT sid="90487" pm="."><plain>The inclusion criteria for patients were the following: (1) meeting diagnostic criteria for schizophrenia according to the Diagnostic and Statistical Manual of Mental Disorders, Fourth Edition based on the Mini-International Neuropsychiatric Interview; (2) aged 18–80, ethnically Han Chinese; (3) had a duration of schizophrenia ≥4 years; (4) experienced multiple psychotic episodes ≧2 times; and (5) on stable antipsychotic treatment with either chlorpromazine or olanzapine ≧12 months (without dose change for at least 30 days). </plain></SENT>
<SENT sid="90488" pm="."><plain>None of the participants in the control group had a personal or family history of psychotic disorders as assessed by two experienced psychiatrists. </plain></SENT>
</text></p><p><text><SENT sid="90489" pm="."><plain>The exclusion criteria were the following: (1) were diagnosed with schizoaffective disorder, mental retardation, substance abuse, cognitive disorders or other mental disorder; (2) had a severe neuroendocrine or metabolic medical condition, or immunologic alterations other than those related to antipsychotics; and (3) were pregnant or nursing. </plain></SENT>
</text></p><p><text><SENT sid="90490" pm="."><plain>After strict screening, 75 patients were included in our study while 10 were excluded for the following reasons: six patients declined to participate in, three patients had metabolic or neuroendocrine disease and one patient was diagnosed with schizoaffective disorder. </plain></SENT>
<SENT sid="90491" pm="."><plain>Fifty healthy controls were included in the study while two were excluded because of physical condition (as shown in figure 1). </plain></SENT>
</text></p><p><text><SENT sid="90492" pm="."><plain>All participants provided written informed consent. </plain></SENT>
<SENT sid="90493" pm="."><plain>Demographic data, physical examination and blood samples were collected from all subjects. </plain></SENT>
</text></p></sec><sec id="s2-2"><title><text><SENT sid="90494" pm="."><plain>Clinical evaluation </plain></SENT>
</text></title><p><text><SENT sid="90495" pm="."><plain>The patients’ psychopathology was evaluated by two psychiatrists with clinical experience for more than or equal to 5 years, using the Positive and Negative Syndrome Scale (PANSS)23 and the Brief Psychiatric Rating Scale (BPRS).23 24 Training consistency of PANSS and BPRS was conducted between the two psychiatrists before the evaluation. </plain></SENT>
<SENT sid="90496" pm="."><plain>Thereafter, an intraclass correlation coefficient ≧0.8 was maintained at repeated evaluation in this study. </plain></SENT>
</text></p><p><text><SENT sid="90497" pm="."><plain>Although the items of PANSS were originally grouped into three subscales,25 factor analyses indicated that a five-factor model may better characterise PANSS data: positive factor (items P1, P3, P5, G9), negative factor (items N1, N2, N3, N4, N6, G7), cognitive factor (items P2, N5, G11), excited factor (items P4, P7, G8, G14) and depressed factor (items G2, G3, G6).26 27 </plain></SENT>
</text></p></sec><sec id="s2-3"><title><text><SENT sid="90498" pm="."><plain>Measurement of plasma leptin, glucose and lipid profiles </plain></SENT>
</text></title><p><text><SENT sid="90499" pm="."><plain>All blood samples were collected from subjects between 07:00 and 09:00 following an overnight fast. </plain></SENT>
<SENT sid="90500" pm="."><plain>Plasma was then separated, aliquoted and stored at −80°C. </plain></SENT>
<SENT sid="90501" pm="."><plain>Plasma leptin levels were measured in triplicate by using commercial ELISA kit (R&amp;D Systems, USA). </plain></SENT>
<SENT sid="90502" pm="."><plain>All samples were assayed by the same technician who was blind to the clinical status of the samples. </plain></SENT>
<SENT sid="90503" pm="."><plain>The interassay and intra-assay coefficients of variability for leptin were 3.4% and 4.5%, respectively. </plain></SENT>
</text></p></sec><sec id="s2-4"><title><text><SENT sid="90504" pm="."><plain>Statistical analysis </plain></SENT>
</text></title><p><text><SENT sid="90505" pm="."><plain>Statistical analysis was performed by using the Statistical Package for Social Sciences (SPSS, V.23.0; IBM). </plain></SENT>
<SENT sid="90506" pm="."><plain>The Kolmogorov-Smirnov test was used to examine the normal distribution of data. </plain></SENT>
<SENT sid="90507" pm="."><plain>Because of the non-normal distribution, the concentration of leptin was converted into lg (leptin) before further statistical analysis. </plain></SENT>
<SENT sid="90508" pm="."><plain>Independent samples t-test for continuous variables and χ 2 test for categorical variables were respectively used to compare demographic data and clinical variables between groups. </plain></SENT>
<SENT sid="90509" pm="."><plain>Analysis of covariance (ANCOVA) was further used to control for confounding effects of gender, age and BMI on leptin levels. </plain></SENT>
<SENT sid="90510" pm="."><plain>Spearman’s r test was used to examine the correlation between leptin and psychopathological variables when controlled for gender, age and BMI. </plain></SENT>
<SENT sid="90511" pm="."><plain>Multiple stepwise regression analysis was then used to identify significant predictive variables associated with psychopathological variables when controlled for gender, age and BMI. </plain></SENT>
<SENT sid="90512" pm="."><plain>In addition, Bonferroni correction was applied to adjust for multiple testing. </plain></SENT>
<SENT sid="90513" pm="."><plain>All p values were two tailed with the significance level set at 0.05. </plain></SENT>
</text></p></sec></sec></SecTag><SecTag type="RESULTS"><sec sec-type="results" id="s3"><title><text><SENT sid="90514" pm="."><plain>Results </plain></SENT>
</text></title><sec id="s3-1"><title><text><SENT sid="90515" pm="."><plain>Demographic data of patients with schizophrenia and healthy controls </plain></SENT>
</text></title><p><text><SENT sid="90516" pm="."><plain>A total of 75 patients with schizophrenia and 50 healthy subjects were included in this study. </plain></SENT>
<SENT sid="90517" pm="."><plain>One patient was excluded from the analysis as the concentration of his plasma leptin level did not fall within 3 SDs of the mean and was therefore considered an outlier. </plain></SENT>
<SENT sid="90518" pm="."><plain>Hence all analyses were performed on 74 patients and 50 controls. </plain></SENT>
<SENT sid="90519" pm="."><plain>As shown in table 1, no significant differences in gender, age and BMI were found between the patients and controls. </plain></SENT>
</text></p><SecTag type="TABLE"><table-wrap id="T1" orientation="portrait" position="float"><label>Table 1</label><caption><p><text><SENT sid="90520" pm="."><plain>Demographic data and clinical characteristics of the patients with schizophrenia and healthy controls </plain></SENT>
</text></p></caption><table frame="hsides" rules="groups"><thead><tr><td align="left" valign="bottom" rowspan="1" colspan="1"/><td align="left" valign="bottom" rowspan="1" colspan="1"><text><SENT sid="90521" pm="."><plain>Schizophrenia </plain></SENT>
</text></td><td align="left" valign="bottom" rowspan="1" colspan="1"><text><SENT sid="90522" pm="."><plain>Healthy controls </plain></SENT>
</text></td><td align="left" valign="bottom" rowspan="1" colspan="1"><text><SENT sid="90523" pm="."><plain>t or χ 2 </plain></SENT>
</text></td><td align="left" valign="bottom" rowspan="1" colspan="1"><text><SENT sid="90524" pm="."><plain>P values </plain></SENT>
</text></td></tr></thead><tbody><tr><td align="left" valign="top" rowspan="1" colspan="1"><text><SENT sid="90525" pm="."><plain>n </plain></SENT>
</text></td><td align="char" char="." valign="top" rowspan="1" colspan="1"><text><SENT sid="90526" pm="."><plain>74 </plain></SENT>
</text></td><td align="char" char="." valign="top" rowspan="1" colspan="1"><text><SENT sid="90527" pm="."><plain>50 </plain></SENT>
</text></td><td valign="top" align="char" char="." rowspan="1" colspan="1"/><td valign="top" align="char" char="." rowspan="1" colspan="1"/></tr><tr><td align="left" valign="top" rowspan="1" colspan="1"><text><SENT sid="90528" pm="."><plain>Gender </plain></SENT>
</text></td><td valign="top" align="char" char="." rowspan="1" colspan="1"/><td valign="top" align="char" char="." rowspan="1" colspan="1"/><td valign="top" align="char" char="." rowspan="1" colspan="1"/><td valign="top" align="char" char="." rowspan="1" colspan="1"/></tr><tr><td align="left" valign="top" rowspan="1" colspan="1"><text><SENT sid="90529" pm="."><plain> Male (%) </plain></SENT>
</text></td><td valign="top" align="char" char="." rowspan="1" colspan="1"><text><SENT sid="90530" pm="."><plain>50/75 (66.7) </plain></SENT>
</text></td><td valign="top" align="char" char="." rowspan="1" colspan="1"><text><SENT sid="90531" pm="."><plain>35/50 (33.3) </plain></SENT>
</text></td><td align="char" char="." valign="top" rowspan="1" colspan="1"><text><SENT sid="90532" pm="."><plain>0.153 </plain></SENT>
</text></td><td align="char" char="." valign="top" rowspan="1" colspan="1"><text><SENT sid="90533" pm="."><plain>0.696 </plain></SENT>
</text></td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1"><text><SENT sid="90534" pm="."><plain> Female (%) </plain></SENT>
</text></td><td valign="top" align="char" char="." rowspan="1" colspan="1"><text><SENT sid="90535" pm="."><plain>20/75 (70.0) </plain></SENT>
</text></td><td valign="top" align="char" char="." rowspan="1" colspan="1"><text><SENT sid="90536" pm="."><plain>15/50 (30.0) </plain></SENT>
</text></td><td valign="top" align="char" char="." rowspan="1" colspan="1"/><td valign="top" align="char" char="." rowspan="1" colspan="1"/></tr><tr><td align="left" valign="top" rowspan="1" colspan="1"><text><SENT sid="90537" pm="."><plain>Age (years) </plain></SENT>
</text></td><td align="char" char="." valign="top" rowspan="1" colspan="1"><text><SENT sid="90538" pm="."><plain>57.0 (10.3) </plain></SENT>
</text></td><td align="char" char="." valign="top" rowspan="1" colspan="1"><text><SENT sid="90539" pm="."><plain>55.0 (9.6) </plain></SENT>
</text></td><td align="char" char="." valign="top" rowspan="1" colspan="1"><text><SENT sid="90540" pm="."><plain>0.135 </plain></SENT>
</text></td><td align="char" char="." valign="top" rowspan="1" colspan="1"><text><SENT sid="90541" pm="."><plain>0.893 </plain></SENT>
</text></td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1"><text><SENT sid="90542" pm="."><plain>BMI (kg/m2) </plain></SENT>
</text></td><td align="char" char="." valign="top" rowspan="1" colspan="1"><text><SENT sid="90543" pm="."><plain>24.3 (3.4) </plain></SENT>
</text></td><td align="char" char="." valign="top" rowspan="1" colspan="1"><text><SENT sid="90544" pm="."><plain>23.9 (2.9) </plain></SENT>
</text></td><td align="char" char="." valign="top" rowspan="1" colspan="1"><text><SENT sid="90545" pm="."><plain>0.083 </plain></SENT>
</text></td><td align="char" char="." valign="top" rowspan="1" colspan="1"><text><SENT sid="90546" pm="."><plain>0.934 </plain></SENT>
</text></td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1"><text><SENT sid="90547" pm="."><plain>Years of education </plain></SENT>
</text></td><td align="char" char="." valign="top" rowspan="1" colspan="1"><text><SENT sid="90548" pm="."><plain>8.8 (2.2) </plain></SENT>
</text></td><td valign="top" align="char" char="." rowspan="1" colspan="1"/><td valign="top" align="char" char="." rowspan="1" colspan="1"/><td valign="top" align="char" char="." rowspan="1" colspan="1"/></tr><tr><td align="left" valign="top" rowspan="1" colspan="1"><text><SENT sid="90549" pm="."><plain>Age of onset (years) </plain></SENT>
</text></td><td align="char" char="." valign="top" rowspan="1" colspan="1"><text><SENT sid="90550" pm="."><plain>28.2 (9.1) </plain></SENT>
</text></td><td valign="top" align="char" char="." rowspan="1" colspan="1"/><td valign="top" align="char" char="." rowspan="1" colspan="1"/><td valign="top" align="char" char="." rowspan="1" colspan="1"/></tr><tr><td align="left" valign="top" rowspan="1" colspan="1"><text><SENT sid="90551" pm="."><plain>Duration of schizophrenia (years) </plain></SENT>
</text></td><td align="char" char="." valign="top" rowspan="1" colspan="1"><text><SENT sid="90552" pm="."><plain>28.8 (12.8) </plain></SENT>
</text></td><td valign="top" align="char" char="." rowspan="1" colspan="1"/><td valign="top" align="char" char="." rowspan="1" colspan="1"/><td valign="top" align="char" char="." rowspan="1" colspan="1"/></tr><tr><td align="left" valign="top" rowspan="1" colspan="1"><text><SENT sid="90553" pm="."><plain>DUP (months) </plain></SENT>
</text></td><td align="char" char="." valign="top" rowspan="1" colspan="1"><text><SENT sid="90554" pm="."><plain>48.1 (80.2) </plain></SENT>
</text></td><td valign="top" align="char" char="." rowspan="1" colspan="1"/><td valign="top" align="char" char="." rowspan="1" colspan="1"/><td valign="top" align="char" char="." rowspan="1" colspan="1"/></tr><tr><td align="left" valign="top" rowspan="1" colspan="1"><text><SENT sid="90555" pm="."><plain>Number of episodes </plain></SENT>
</text></td><td align="char" char="." valign="top" rowspan="1" colspan="1"><text><SENT sid="90556" pm="."><plain>5.3 (3.2) </plain></SENT>
</text></td><td valign="top" align="char" char="." rowspan="1" colspan="1"/><td valign="top" align="char" char="." rowspan="1" colspan="1"/><td valign="top" align="char" char="." rowspan="1" colspan="1"/></tr><tr><td align="left" valign="top" rowspan="1" colspan="1"><text><SENT sid="90557" pm="."><plain>Daily antipsychotic dosage (mg) (chlorpromazine equivalents*) </plain></SENT>
</text></td><td align="char" char="." valign="top" rowspan="1" colspan="1"><text><SENT sid="90558" pm="."><plain>280.7 (113.3) </plain></SENT>
</text></td><td valign="top" align="char" char="." rowspan="1" colspan="1"/><td valign="top" align="char" char="." rowspan="1" colspan="1"/><td valign="top" align="char" char="." rowspan="1" colspan="1"/></tr><tr><td align="left" valign="top" rowspan="1" colspan="1"><text><SENT sid="90559" pm="."><plain>PANSS total score </plain></SENT>
</text></td><td align="char" char="." valign="top" rowspan="1" colspan="1"><text><SENT sid="90560" pm="."><plain>74.6 (16.2) </plain></SENT>
</text></td><td valign="top" align="char" char="." rowspan="1" colspan="1"/><td valign="top" align="char" char="." rowspan="1" colspan="1"/><td valign="top" align="char" char="." rowspan="1" colspan="1"/></tr><tr><td align="left" valign="top" rowspan="1" colspan="1"><text><SENT sid="90561" pm="."><plain> Positive subscale </plain></SENT>
</text></td><td align="char" char="." valign="top" rowspan="1" colspan="1"><text><SENT sid="90562" pm="."><plain>10.2 (4.4) </plain></SENT>
</text></td><td valign="top" align="char" char="." rowspan="1" colspan="1"/><td valign="top" align="char" char="." rowspan="1" colspan="1"/><td valign="top" align="char" char="." rowspan="1" colspan="1"/></tr><tr><td align="left" valign="top" rowspan="1" colspan="1"><text><SENT sid="90563" pm="."><plain> Negative subscale </plain></SENT>
</text></td><td align="char" char="." valign="top" rowspan="1" colspan="1"><text><SENT sid="90564" pm="."><plain>27.4 (7.9) </plain></SENT>
</text></td><td valign="top" align="char" char="." rowspan="1" colspan="1"/><td valign="top" align="char" char="." rowspan="1" colspan="1"/><td valign="top" align="char" char="." rowspan="1" colspan="1"/></tr><tr><td align="left" valign="top" rowspan="1" colspan="1"><text><SENT sid="90565" pm="."><plain> General psychopathology subscale </plain></SENT>
</text></td><td align="char" char="." valign="top" rowspan="1" colspan="1"><text><SENT sid="90566" pm="."><plain>37.3 (9.8) </plain></SENT>
</text></td><td valign="top" align="char" char="." rowspan="1" colspan="1"/><td valign="top" align="char" char="." rowspan="1" colspan="1"/><td valign="top" align="char" char="." rowspan="1" colspan="1"/></tr><tr><td align="left" valign="top" rowspan="1" colspan="1"><text><SENT sid="90567" pm="."><plain>BPRS total score </plain></SENT>
</text></td><td align="char" char="." valign="top" rowspan="1" colspan="1"><text><SENT sid="90568" pm="."><plain>43.6 (10.3) </plain></SENT>
</text></td><td valign="top" align="char" char="." rowspan="1" colspan="1"/><td valign="top" align="char" char="." rowspan="1" colspan="1"/><td valign="top" align="char" char="." rowspan="1" colspan="1"/></tr></tbody></table><table-wrap-foot><fn id="T1_FN1"><p><text><SENT sid="90569" pm="."><plain>*The chlorpromazine equivalents were calculated as described by Gray et al.42 </plain></SENT>
</text></p></fn><fn id="T1_FN2"><p><text><SENT sid="90570" pm="."><plain>BMI, body mass index; BPRS, Brief Psychiatric Rating Scale; DUP, duration of untreated psychosis; PANSS, Positive and Negative Syndrome Scale. </plain></SENT>
</text></p></fn></table-wrap-foot></table-wrap></SecTag></sec><sec id="s3-2"><title><text><SENT sid="90571" pm="."><plain>Plasma leptin levels in patients with schizophrenia and healthy controls </plain></SENT>
</text></title><p><text><SENT sid="90572" pm="."><plain>Logarithmic transformed plasma leptin levels (lg leptin) were significantly higher in patients with schizophrenia than in healthy controls (figure 2). </plain></SENT>
<SENT sid="90573" pm="."><plain>When gender, age and BMI were added as potential confounding covariates to ANCOVA, the differences between groups remained significant (F=25.79, df=1, p&lt;0.001). </plain></SENT>
</text></p><SecTag type="FIG"><fig id="F2" orientation="portrait" position="float"><label>Figure 2</label><caption><p><text><SENT sid="90574" pm="."><plain>Logarithmic transformed plasma leptin levels (lg leptin) in patients with schizophrenia (n=74) and healthy controls (n=50). </plain></SENT>
<SENT sid="90575" pm="."><plain>The sample means are indicated by the black bars. </plain></SENT>
<SENT sid="90576" pm="."><plain>Plasma lg leptin levels were significantly higher in patients with schizophrenia than healthy controls. </plain></SENT>
</text></p></caption><graphic xlink:href="gpsych-2018-100018f02"/></fig></SecTag></sec><sec id="s3-3"><title><text><SENT sid="90577" pm="."><plain>Association between leptin levels and psychopathology in schizophrenia </plain></SENT>
</text></title><p><text><SENT sid="90578" pm="."><plain>When controlled for gender, age and BMI, partial correlation analysis indicated a significantly negative association between plasma leptin levels and the PANSS depression factor scores (r=−0.255, Bonferroni corrected p=0.028, as shown in table 2). </plain></SENT>
</text></p><SecTag type="TABLE"><table-wrap id="T2" orientation="portrait" position="float"><label>Table 2</label><caption><p><text><SENT sid="90579" pm="."><plain>Partial correlations between leptin levels and clinical variables in patients with schizophrenia, controlled for gender, age and BMI (Spearman's r) (n=74) </plain></SENT>
</text></p></caption><table frame="hsides" rules="groups"><thead><tr><td align="left" valign="bottom" rowspan="1" colspan="1"/><td align="left" valign="bottom" rowspan="1" colspan="1"><text><SENT sid="90580" pm="."><plain>Correlation coefficient </plain></SENT>
</text></td><td align="left" valign="bottom" rowspan="1" colspan="1"><text><SENT sid="90581" pm="."><plain>P values </plain></SENT>
</text></td></tr></thead><tbody><tr><td align="left" valign="top" rowspan="1" colspan="1"><text><SENT sid="90582" pm="."><plain>PANSS total score </plain></SENT>
</text></td><td align="char" char="." valign="top" rowspan="1" colspan="1"><text><SENT sid="90583" pm="."><plain>−0.039 </plain></SENT>
</text></td><td align="char" char="." valign="top" rowspan="1" colspan="1"><text><SENT sid="90584" pm="."><plain>0.745 </plain></SENT>
</text></td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1"><text><SENT sid="90585" pm="."><plain> Positive factor </plain></SENT>
</text></td><td align="char" char="." valign="top" rowspan="1" colspan="1"><text><SENT sid="90586" pm="."><plain>0.141 </plain></SENT>
</text></td><td align="char" char="." valign="top" rowspan="1" colspan="1"><text><SENT sid="90587" pm="."><plain>0.230 </plain></SENT>
</text></td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1"><text><SENT sid="90588" pm="."><plain> Negative factor </plain></SENT>
</text></td><td align="char" char="." valign="top" rowspan="1" colspan="1"><text><SENT sid="90589" pm="."><plain>−0.970 </plain></SENT>
</text></td><td align="char" char="." valign="top" rowspan="1" colspan="1"><text><SENT sid="90590" pm="."><plain>0.412 </plain></SENT>
</text></td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1"><text><SENT sid="90591" pm="."><plain> Cognitive factor </plain></SENT>
</text></td><td align="char" char="." valign="top" rowspan="1" colspan="1"><text><SENT sid="90592" pm="."><plain>−0.045 </plain></SENT>
</text></td><td align="char" char="." valign="top" rowspan="1" colspan="1"><text><SENT sid="90593" pm="."><plain>0.707 </plain></SENT>
</text></td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1"><text><SENT sid="90594" pm="."><plain> Excited factor </plain></SENT>
</text></td><td align="char" char="." valign="top" rowspan="1" colspan="1"><text><SENT sid="90595" pm="."><plain>0.139 </plain></SENT>
</text></td><td align="char" char="." valign="top" rowspan="1" colspan="1"><text><SENT sid="90596" pm="."><plain>0.236 </plain></SENT>
</text></td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1"><text><SENT sid="90597" pm="."><plain> Depressed factor </plain></SENT>
</text></td><td align="char" char="." valign="top" rowspan="1" colspan="1"><text><SENT sid="90598" pm="."><plain>−0.255 </plain></SENT>
</text></td><td valign="top" align="char" char="." rowspan="1" colspan="1"><text><SENT sid="90599" pm="."><plain>0.028* </plain></SENT>
</text></td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1"><text><SENT sid="90600" pm="."><plain>BPRS total score </plain></SENT>
</text></td><td align="char" char="." valign="top" rowspan="1" colspan="1"><text><SENT sid="90601" pm="."><plain>−0.074 </plain></SENT>
</text></td><td align="char" char="." valign="top" rowspan="1" colspan="1"><text><SENT sid="90602" pm="."><plain>0.535 </plain></SENT>
</text></td></tr></tbody></table><table-wrap-foot><fn id="T2_FN1"><p><text><SENT sid="90603" pm="."><plain>*Indicated the Bonferroni corrected p value, p&lt;0.05. </plain></SENT>
</text></p></fn><fn id="T2_FN2"><p><text><SENT sid="90604" pm="."><plain>BMI, body mass index; BPRS, Brief Psychiatric Rating Scale; PANSS, Positive and Negative Syndrome Scale. </plain></SENT>
</text></p></fn></table-wrap-foot></table-wrap></SecTag><p><text><SENT sid="90605" pm="."><plain>Furthermore, a multiple stepwise regression was run to predict the PANSS depression factor with leptin levels and demographics including years of education, age of onset, duration of schizophrenia, duration of untreated psychosis, number of episodes and daily antipsychotic dosage. </plain></SENT>
<SENT sid="90606" pm="."><plain>When adjusted for gender, age and BMI, leptin levels were identified as a significant predictor for the PANSS depression factor (β=−0.33, t=−2.32, p=0.024) (β=−0.26, t=−1.79, p=0.032). </plain></SENT>
</text></p><p><text><SENT sid="90607" pm="."><plain>According to the criteria of PANSS depression factor score &gt;3, forty-seven of the 74 patients with schizophrenia had depressive symptoms. </plain></SENT>
<SENT sid="90608" pm="."><plain>In the depressive symptom group, correlation analysis (r=−0.303, Bonferroni corrected p=0.038, as shown in table 3) and regression analysis (β=−0.26, t=−1.79, p=0.032) further confirmed that plasma leptin levels were significantly negatively associated with the PANSS depressed factor. </plain></SENT>
</text></p><SecTag type="TABLE"><table-wrap id="T3" orientation="portrait" position="float"><label>Table 3</label><caption><p><text><SENT sid="90609" pm="."><plain>Partial correlations between leptin levels and clinical variables in schizophrenia with depressive symptoms, controlled for gender, age and BMI (Spearman's r) (n=47) </plain></SENT>
</text></p></caption><table frame="hsides" rules="groups"><thead><tr><td align="left" valign="bottom" rowspan="1" colspan="1"/><td align="left" valign="bottom" rowspan="1" colspan="1"><text><SENT sid="90610" pm="."><plain>Correlation coefficient </plain></SENT>
</text></td><td align="left" valign="bottom" rowspan="1" colspan="1"><text><SENT sid="90611" pm="."><plain>P values </plain></SENT>
</text></td></tr></thead><tbody><tr><td align="left" valign="top" rowspan="1" colspan="1"><text><SENT sid="90612" pm="."><plain>PANSS total score </plain></SENT>
</text></td><td align="char" char="." valign="top" rowspan="1" colspan="1"><text><SENT sid="90613" pm="."><plain>0.008 </plain></SENT>
</text></td><td align="char" char="." valign="top" rowspan="1" colspan="1"><text><SENT sid="90614" pm="."><plain>0.958 </plain></SENT>
</text></td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1"><text><SENT sid="90615" pm="."><plain> Positive factor </plain></SENT>
</text></td><td align="char" char="." valign="top" rowspan="1" colspan="1"><text><SENT sid="90616" pm="."><plain>0.23 </plain></SENT>
</text></td><td align="char" char="." valign="top" rowspan="1" colspan="1"><text><SENT sid="90617" pm="."><plain>0.121 </plain></SENT>
</text></td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1"><text><SENT sid="90618" pm="."><plain> Negative factor </plain></SENT>
</text></td><td align="char" char="." valign="top" rowspan="1" colspan="1"><text><SENT sid="90619" pm="."><plain>−0.069 </plain></SENT>
</text></td><td align="char" char="." valign="top" rowspan="1" colspan="1"><text><SENT sid="90620" pm="."><plain>0.644 </plain></SENT>
</text></td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1"><text><SENT sid="90621" pm="."><plain> Cognitive factor </plain></SENT>
</text></td><td align="char" char="." valign="top" rowspan="1" colspan="1"><text><SENT sid="90622" pm="."><plain>0.069 </plain></SENT>
</text></td><td align="char" char="." valign="top" rowspan="1" colspan="1"><text><SENT sid="90623" pm="."><plain>0.644 </plain></SENT>
</text></td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1"><text><SENT sid="90624" pm="."><plain> Excited factor </plain></SENT>
</text></td><td align="char" char="." valign="top" rowspan="1" colspan="1"><text><SENT sid="90625" pm="."><plain>0.373 </plain></SENT>
</text></td><td align="char" char="." valign="top" rowspan="1" colspan="1"><text><SENT sid="90626" pm="."><plain>0.352 </plain></SENT>
</text></td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1"><text><SENT sid="90627" pm="."><plain> Depressed factor </plain></SENT>
</text></td><td align="char" char="." valign="top" rowspan="1" colspan="1"><text><SENT sid="90628" pm="."><plain>−0.303 </plain></SENT>
</text></td><td valign="top" align="char" char="." rowspan="1" colspan="1"><text><SENT sid="90629" pm="."><plain>0.038* </plain></SENT>
</text></td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1"><text><SENT sid="90630" pm="."><plain>BPRS total score </plain></SENT>
</text></td><td align="char" char="." valign="top" rowspan="1" colspan="1"><text><SENT sid="90631" pm="."><plain>−0.04 </plain></SENT>
</text></td><td align="char" char="." valign="top" rowspan="1" colspan="1"><text><SENT sid="90632" pm="."><plain>0.789 </plain></SENT>
</text></td></tr></tbody></table><table-wrap-foot><fn id="T3_FN1"><p><text><SENT sid="90633" pm="."><plain>*Indicated the Bonferroni corrected p value, p&lt;0.05. </plain></SENT>
</text></p></fn><fn id="T3_FN2"><p><text><SENT sid="90634" pm="."><plain>BMI, body mass index; BPRS, Brief Psychiatric Rating Scale; PANSS, Positive and Negative Syndrome Scale. </plain></SENT>
</text></p></fn></table-wrap-foot></table-wrap></SecTag></sec></sec></SecTag><SecTag type="DISCUSS"><sec sec-type="discussion" id="s4"><title><text><SENT sid="90635" pm="."><plain>Discussion </plain></SENT>
</text></title><sec id="s4-1"><title><text><SENT sid="90636" pm="."><plain>Main findings </plain></SENT>
</text></title><p><text><SENT sid="90637" pm="."><plain>This study had two main findings. </plain></SENT>
<SENT sid="90638" pm="."><plain>(1) Plasma leptin levels were significantly increased in patients with schizophrenia compared with the healthy controls despite controlling for gender, age and BMI. </plain></SENT>
<SENT sid="90639" pm="."><plain>(2) Plasma leptin levels were significantly negatively associated with the PANSS depressed factor but not with other factor components. </plain></SENT>
</text></p><p><text><SENT sid="90640" pm="."><plain>In this study, we observed significantly higher plasma leptin levels in patients with chronic schizophrenia, which was in agreement with previous studies.16 28 29 Early research focused primarily on the relationship between leptin levels and weight changes associated with antipsychotic treatment. </plain></SENT>
<SENT sid="90641" pm="."><plain>Many studies reported that the elevated leptin levels in patients with schizophrenia were largely dependent on weight gain and BMI. </plain></SENT>
<SENT sid="90642" pm="."><plain>However, few of these studies considered that a difference in BMI existed between groups when they compared leptin levels. </plain></SENT>
<SENT sid="90643" pm="."><plain>On the contrary, gender, age and BMI were taken into account, and the difference of leptin levels between the patients and controls remained significant. </plain></SENT>
<SENT sid="90644" pm="."><plain>Likewise, Kim and colleagues recently found that plasma leptin levels tended to be higher in patients with schizophrenia than in age-matched and BMI-matched healthy controls.30 A recent meta-analysis also found that schizophrenia was associated with elevated blood leptin levels compared with controls, but the difference in leptin levels between groups was not moderated by BMI. </plain></SENT>
<SENT sid="90645" pm="."><plain>Taken together, these studies suggest that leptin levels may be associated with multiple factors, for example, the psychopathology of schizophrenia, different phases of illness and lifestyles. </plain></SENT>
</text></p><p><text><SENT sid="90646" pm="."><plain>In our present study, it was further found that there was a significant negative correlation between plasma leptin levels and the PANSS depressed factor subscore in patients with schizophrenia. </plain></SENT>
<SENT sid="90647" pm="."><plain>Previous studies observed decreased plasma leptin levels in patients with or without comorbid major depression compared with controls.31 32 Furthermore, studies found that the negative relationship between leptin levels and the severity of depressive symptoms was independent of body weight or BMI.28 33 34 In consistency with these findings, our study also found a link between leptin levels and depressive symptoms in patients with schizophrenia after controlling for BMI. </plain></SENT>
</text></p></sec><sec id="s4-2"><title><text><SENT sid="90648" pm="."><plain>Limitations </plain></SENT>
</text></title><p><text><SENT sid="90649" pm="."><plain>Several limitations of this study should be noted. </plain></SENT>
<SENT sid="90650" pm="."><plain>First, due to the nature of cross-sectional studies, the patients’ baseline information was unknown (eg, plasma leptin levels, psychopathological symptoms and previous medication use) and therefore the results obtained in this study may be confounded. </plain></SENT>
<SENT sid="90651" pm="."><plain>Second, as the sample size is small and leptin level is fluctuated, our findings should be accordingly considered as preliminary exploration. </plain></SENT>
<SENT sid="90652" pm="."><plain>Last, it is worth mentioning that the depressed factor used in the present study is derived from the five-factor model of PANSS scale, which is used for symptomatology. </plain></SENT>
<SENT sid="90653" pm="."><plain>A specific depression scale such as Hamilton Depression Rating Scale may have been a better choice. </plain></SENT>
<SENT sid="90654" pm="."><plain>Therefore, in order to get a conclusive and not just suggestive result, the relationship between leptin and depressive symptomology in schizophrenia deserves further investigation using a specific depression scale in a large-scale longitudinal study, or even a randomised, double-blind and parallel controlled clinical trial. </plain></SENT>
</text></p></sec><sec id="s4-3"><title><text><SENT sid="90655" pm="."><plain>Implications </plain></SENT>
</text></title><p><text><SENT sid="90656" pm="."><plain>Different theories have been proposed in the literature to explain the negative relationship between plasma leptin levels and the depressive symptoms. </plain></SENT>
</text></p><p><text><SENT sid="90657" pm="."><plain>First, leptin may be involved in regulation of serotonin (5-HT) and dopamine (DA), which are the key neurotransmitters in the classic aetiological hypothesis of depression. </plain></SENT>
<SENT sid="90658" pm="."><plain>Previous studies have found that intraperitoneal administration of leptin dose dependently significantly increased serum 5-HT levels,35 while leptin-deficient ob/ob mice exhibited impaired DA functions and decreased DA release.36 Second, leptin may have direct and indirect neurotrophic effects, which are disrupted in depression. </plain></SENT>
<SENT sid="90659" pm="."><plain>Previous studies showed that leptin administration elevated the expression of brain-derived neurotrophic factor, one of the most important neurotrophic factors.37 Leptin-deficient ob/ob mice showed decreased weight overall for the whole brain and decreased volume of specific brain regions, while these neurodegenerative changes were partially reversed by leptin treatment.35 37–40 Third, leptin may be a potent inhibitor of the hypothalamic-pituitary-adrenal axis, which is overactive in depression.41 </plain></SENT>
</text></p><p><text><SENT sid="90660" pm="."><plain>To our knowledge, this is the first study to explore the relationship between leptin levels and depressive symptoms in schizophrenia, while previous studies focused mainly on major depressive disorder. </plain></SENT>
<SENT sid="90661" pm="."><plain>If our results could be confirmed in further large-scale longitudinal studies, plasma leptin level would probably serve as a promising predictor for depressive symptoms in schizophrenia. </plain></SENT>
</text></p></sec></sec></SecTag></body><back><SecTag type="ACK_FUND"><ack><p><text4fund><text><SENT sid="90662" pm="."><plain>The authors gratefully acknowledge all subjects for their participation in the current study. </plain></SENT>
</text></text4fund></p></ack></SecTag><fn-group><fn fn-type="other"><p><text><SENT sid="90663" pm="."><plain>JX and YJ contributed equally. </plain></SENT>
</text></p></fn><fn fn-type="other"><p><text><SENT sid="90664" pm="."><plain>Authors’ contributions: DC and DQ were responsible for study design and revising. </plain></SENT>
<SENT sid="90665" pm="."><plain>JX, MX, YL, YS and WD were responsible for clinical data collection and lab experiments. </plain></SENT>
<SENT sid="90666" pm="."><plain>JX, YJ and DQ managed the literature search and the statistical analyses. </plain></SENT>
<SENT sid="90667" pm="."><plain>JX drafted the manuscript. </plain></SENT>
<SENT sid="90668" pm="."><plain>DC, DQ, YP and CZ participated in revising the manuscript. </plain></SENT>
<SENT sid="90669" pm="."><plain>All authors read and approved the final manuscript. </plain></SENT>
</text></p></fn><SecTag type="ACK_FUND"><fn fn-type="other"><p><text4fund><text><SENT sid="90670" pm="."><plain>Funding: This study was supported by grants from the National Key R&amp;D Program of China (2017YFC0909200), the National Science Foundation of China (NSFC; 81171266, 81271481, 81671336 and 81500976), the China and National Key Research and Development Program (2017YFC0909200), the Shanghai Key Laboratory of Psychotic Disorders (13dz2260500), the Shanghai Municipal Planning Commission of Science and Research Fund (20154Y0194) and the Canadian Institutes of Health Research (project grant PJT-156116). </plain></SENT>
</text></text4fund></p></fn></SecTag><fn fn-type="COI-statement"><p><text><SENT sid="90671" pm="."><plain>Competing interests: None declared. </plain></SENT>
</text></p></fn><fn fn-type="other"><p><text><SENT sid="90672" pm="."><plain>Informed consent: Obtained. </plain></SENT>
</text></p></fn><fn fn-type="other"><p><text><SENT sid="90673" pm="."><plain>Ethics approval: Institutional Review Board of Shanghai Mental Health Center. </plain></SENT>
</text></p></fn><fn fn-type="other"><p><text><SENT sid="90674" pm="."><plain>Provenance and peer review: Not commissioned; externally peer reviewed. </plain></SENT>
</text></p></fn><fn fn-type="other"><p><text><SENT sid="90675" pm="."><plain>Data sharing statement: No additional data are available. </plain></SENT>
</text></p></fn></fn-group><bio id="d35e44"><p><inline-graphic xlink:href="gpsych-2018-100018ileq01.gif"/> Jinjie Xu graduated with a bachelor’s degree from Nanjing Medical University in 2013 and a master’s degree from Shanghai Mental Health Center, Shanghai Jiao Tong University, School of Medicine in 2017. She began her residency at Beijing Anding Hospital in 2017 and is now a full-time resident doctor. Her main interests are clinical studies of mental disorders.</p></bio><SecTag type="REF"><ref-list><title>References</title><ref id="R1"><text><SENT sid="90676" pm="."><plain>1. Association AP Diagnostic and statistical manual of mental disorders (DSM-5). American Psychiatric Pub, 2013. </plain></SENT>
</text></ref><ref id="R2"><text><SENT sid="90677" pm="."><plain>2. BarbatoA Psychiatry in transition: outcomes of mental health policy shift in Italy. Aust N Z J Psychiatry 1998;32:673–9. 10.3109/00048679809113122 9805590 </plain></SENT>
</text></ref><ref id="R3"><text><SENT sid="90678" pm="."><plain>3. StahlSM Stahl's essential psychopharmacology: neuroscientific basis and practical applications. Cambridge university press, 2013. </plain></SENT>
</text></ref><ref id="R4"><text><SENT sid="90679" pm="."><plain>4. PlananskyK, JohnstonR Depressive syndrome in schizophrenia. Acta Psychiatr Scand 1978;57:207–18. 10.1111/j.1600-0447.1978.tb06887.x 645411 </plain></SENT>
</text></ref><ref id="R5"><text><SENT sid="90680" pm="."><plain>5. ConusP, Abdel-BakiA, HarriganS, et al Pre-morbid and outcome correlates of first episode mania with psychosis: is a distinction between schizoaffective and bipolar I disorder valid in the early phase of psychotic disorders? J Affect Disord 2010;126:88–95. 10.1016/j.jad.2010.04.001 20434220 </plain></SENT>
</text></ref><ref id="R6"><text><SENT sid="90681" pm="."><plain>6. ConleyRR, Ascher-SvanumH, ZhuB, et al The burden of depressive symptoms in the long-term treatment of patients with schizophrenia. Schizophr Res 2007;90:186–97. 10.1016/j.schres.2006.09.027 17110087 </plain></SENT>
</text></ref><ref id="R7"><text><SENT sid="90682" pm="."><plain>7. BuckleyPF, MillerBJ, LehrerDS, et al Psychiatric comorbidities and schizophrenia. Schizophr Bull 2009;35:383–402. 10.1093/schbul/sbn135 19011234 </plain></SENT>
</text></ref><ref id="R8"><text><SENT sid="90683" pm="."><plain>8. SirisSG Suicide and schizophrenia. J Psychopharmacol 2001;15:127–35. 10.1177/026988110101500209 11448086 </plain></SENT>
</text></ref><ref id="R9"><text><SENT sid="90684" pm="."><plain>9. PalmerBA, PankratzVS, BostwickJM The lifetime risk of suicide in schizophrenia: a reexamination. Arch Gen Psychiatry 2005;62:247–53. 10.1001/archpsyc.62.3.247 15753237 </plain></SENT>
</text></ref><ref id="R10"><text><SENT sid="90685" pm="."><plain>10. HawtonK, SuttonL, HawC, et al Schizophrenia and suicide: systematic review of risk factors. Br J Psychiatry 2005;187:9–20. 10.1192/bjp.187.1.9 15994566 </plain></SENT>
</text></ref><ref id="R11"><text><SENT sid="90686" pm="."><plain>11. CarpenterWT, HeinrichsDW, AlphsLD Treatment of negative symptoms. Schizophr Bull 1985;11:440–52. 10.1093/schbul/11.3.440 2863871 </plain></SENT>
</text></ref><ref id="R12"><text><SENT sid="90687" pm="."><plain>12. AndreasenNC, OlsenS Negative v positive schizophrenia. </plain></SENT>
<SENT sid="90688" pm="."><plain>Definition and validation. Arch Gen Psychiatry 1982;39:789–94.7165478 </plain></SENT>
</text></ref><ref id="R13"><text><SENT sid="90689" pm="."><plain>13. ElmquistJK, BjørbaekC, AhimaRS, et al Distributions of leptin receptor mRNA isoforms in the rat brain. J Comp Neurol 1998;395:535–47. 10.1002/(SICI)1096-9861(19980615)395:4&lt;535::AID-CNE9&gt;3.0.CO;2-2 9619505 </plain></SENT>
</text></ref><ref id="R14"><text><SENT sid="90690" pm="."><plain>14. PanW, KastinAJ Leptin: a biomarker for sleep disorders? Sleep Med Rev 2014;18:283–90. 10.1016/j.smrv.2013.07.003 24080454 </plain></SENT>
</text></ref><ref id="R15"><text><SENT sid="90691" pm="."><plain>15. TezapsidisN, JohnstonJM, SmithMA, et al Leptin: a novel therapeutic strategy for Alzheimer's disease. J Alzheimers Dis 2009;16:731–40. 10.3233/JAD-2009-1021 19387109 </plain></SENT>
</text></ref><ref id="R16"><text><SENT sid="90692" pm="."><plain>16. SentissiO, EpelbaumJ, OliéJP, et al Leptin and ghrelin levels in patients with schizophrenia during different antipsychotics treatment: a review. Schizophr Bull 2008;34:1189–99. 10.1093/schbul/sbm141 18165262 </plain></SENT>
</text></ref><ref id="R17"><text><SENT sid="90693" pm="."><plain>17. CasanuevaFF, DieguezC, PopovicV, et al Serum immunoreactive leptin concentrations in patients with anorexia nervosa before and after partial weight recovery. Biochem Mol Med 1997;60:116–20. 10.1006/bmme.1996.2564 9169091 </plain></SENT>
</text></ref><ref id="R18"><text><SENT sid="90694" pm="."><plain>18. LuXY The leptin hypothesis of depression: a potential link between mood disorders and obesity? Curr Opin Pharmacol 2007;7:648–52. 10.1016/j.coph.2007.10.010 18032111 </plain></SENT>
</text></ref><ref id="R19"><text><SENT sid="90695" pm="."><plain>19. SchillingC, GillesM, BlumWF, et al Leptin plasma concentrations increase during antidepressant treatment with amitriptyline and mirtazapine, but not paroxetine and venlafaxine: leptin resistance mediated by antihistaminergic activity? J Clin Psychopharmacol 2013;33:99–103. 10.1097/JCP.0b013e31827cb179 23277262 </plain></SENT>
</text></ref><ref id="R20"><text><SENT sid="90696" pm="."><plain>20. EselE, OzsoyS, TutusA, et al Effects of antidepressant treatment and of gender on serum leptin levels in patients with major depression. Prog Neuropsychopharmacol Biol Psychiatry 2005;29:565–70. 10.1016/j.pnpbp.2005.01.009 15866359 </plain></SENT>
</text></ref><ref id="R21"><text><SENT sid="90697" pm="."><plain>21. PascoJA, JackaFN, WilliamsLJ, et al Leptin in depressed women: cross-sectional and longitudinal data from an epidemiologic study. J Affect Disord 2008;107(1-3):221–5. 10.1016/j.jad.2007.07.024 17727958 </plain></SENT>
</text></ref><ref id="R22"><text><SENT sid="90698" pm="."><plain>22. KrausT, HaackM, SchuldA, et al Low leptin levels but Norma body mass indices in patients with depression or schizophrenia. Neuroendocrinology 2001;73:243–7. 10.1159/000054641 11340338 </plain></SENT>
</text></ref><ref id="R23"><text><SENT sid="90699" pm="."><plain>23. KaySR, FiszbeinA, OplerLA, Positive and negative syndrome scale (PANSS). MHS, 2012. </plain></SENT>
</text></ref><ref id="R24"><text><SENT sid="90700" pm="."><plain>24. FaustmanWO, OverallJE Brief psychiatric rating scale, 1999. </plain></SENT>
</text></ref><ref id="R25"><text><SENT sid="90701" pm="."><plain>25. KaySR, FiszbeinA, OplerLA The positive and negative syndrome scale (PANSS) for schizophrenia. Schizophr Bull 1987;13:261–76. 10.1093/schbul/13.2.261 3616518 </plain></SENT>
</text></ref><ref id="R26"><text><SENT sid="90702" pm="."><plain>26. CitromeL, MengX, HochfeldM Efficacy of iloperidone in schizophrenia: a PANSS five-factor analysis. Schizophr Res 2011;131:75–81. 10.1016/j.schres.2011.05.018 21700430 </plain></SENT>
</text></ref><ref id="R27"><text><SENT sid="90703" pm="."><plain>27. WallworkRS, FortgangR, HashimotoR, et al Searching for a consensus five-factor model of the Positive and Negative Syndrome Scale for schizophrenia. Schizophr Res 2012;137:246–50. 10.1016/j.schres.2012.01.031 22356801 </plain></SENT>
</text></ref><ref id="R28"><text><SENT sid="90704" pm="."><plain>28. JowGM, YangTT, ChenCL Leptin and cholesterol levels are low in major depressive disorder, but high in schizophrenia. J Affect Disord 2006;90:21–7. 10.1016/j.jad.2005.09.015 16324751 </plain></SENT>
</text></ref><ref id="R29"><text><SENT sid="90705" pm="."><plain>29. MelkerssonKI, HultingAL, BrismarKE Elevated levels of insulin, leptin, and blood lipids in olanzapine-treated patients with schizophrenia or related psychoses. J Clin Psychiatry 2000;61:742–9. 10.4088/JCP.v61n1006 11078035 </plain></SENT>
</text></ref><ref id="R30"><text><SENT sid="90706" pm="."><plain>30. KimJH, KimJH, ParkPW, et al Body and liver fat content and adipokines in schizophrenia: a magnetic resonance imaging and spectroscopy study. Psychopharmacology 2017;234:1923–32. 10.1007/s00213-017-4598-5 28315932 </plain></SENT>
</text></ref><ref id="R31"><text><SENT sid="90707" pm="."><plain>31. AtmacaM, KulogluM, TezcanE, et al Serum leptin and cholesterol levels in patients with bipolar disorder. Neuropsychobiology 2002;46:176–9. 10.1159/000067809 12566933 </plain></SENT>
</text></ref><ref id="R32"><text><SENT sid="90708" pm="."><plain>32. EmülHM, SerteserM, KurtE, et al Ghrelin and leptin levels in patients with obsessive-compulsive disorder. Prog Neuropsychopharmacol Biol Psychiatry 2007;31:1270–4. 10.1016/j.pnpbp.2007.05.007 17597276 </plain></SENT>
</text></ref><ref id="R33"><text><SENT sid="90709" pm="."><plain>33. KrausT, HaackM, SchuldA Low leptin levels but normal body mass indices in patients with depression or schizophrenia. Neuroendocrinology 2001;7354641:243–7. 10.1159/000054641  </plain></SENT>
</text></ref><ref id="R34"><text><SENT sid="90710" pm="."><plain>34. LawsonEA, MillerKK, BlumJI, et al Leptin levels are associated with decreased depressive symptoms in women across the weight spectrum, independent of body fat. Clin Endocrinol 2012;76:520–5. 10.1111/j.1365-2265.2011.04182.x  </plain></SENT>
</text></ref><ref id="R35"><text><SENT sid="90711" pm="."><plain>35. HaleemDJ, HaqueZ, InamQU, et al Behavioral, hormonal and central serotonin modulating effects of injected leptin. Peptides 2015;74:1–8. 10.1016/j.peptides.2015.10.002 26456504 </plain></SENT>
</text></ref><ref id="R36"><text><SENT sid="90712" pm="."><plain>36. FultonS, PissiosP, ManchonRP, et al Leptin regulation of the mesoaccumbens dopamine pathway. Neuron 2006;51:811–22. 10.1016/j.neuron.2006.09.006 16982425 </plain></SENT>
</text></ref><ref id="R37"><text><SENT sid="90713" pm="."><plain>37. KomoriT, MorikawaY, NanjoK, et al Induction of brain-derived neurotrophic factor by leptin in the ventromedial hypothalamus. Neuroscience 2006;139:1107–15. 10.1016/j.neuroscience.2005.12.066 16564638 </plain></SENT>
</text></ref><ref id="R38"><text><SENT sid="90714" pm="."><plain>38. FarrSA, BanksWA, MorleyJE Effects of leptin on memory processing. Peptides 2006;27:1420–5. 10.1016/j.peptides.2005.10.006 16293343 </plain></SENT>
</text></ref><ref id="R39"><text><SENT sid="90715" pm="."><plain>39. DrelVR, MashtalirN, IlnytskaO, et al The leptin-deficient (ob/ob) mouse: a new animal model of peripheral neuropathy of type 2 diabetes and obesity. Diabetes 2006;55:3335–43. 10.2337/db06-0885 17130477 </plain></SENT>
</text></ref><ref id="R40"><text><SENT sid="90716" pm="."><plain>40. SchwartzMW, BaskinDG, BukowskiTR, et al Specificity of leptin action on elevated blood glucose levels and hypothalamic neuropeptide Y gene expression in ob/ob mice. Diabetes 1996;45:531–5. 10.2337/diab.45.4.531 8603777 </plain></SENT>
</text></ref><ref id="R41"><text><SENT sid="90717" pm="."><plain>41. FlakJN A role for leptin-regulated neurocircuitry in subordination stress. Physiol Behav 2017;178:144–50. 10.1016/j.physbeh.2016.11.019 27887997 </plain></SENT>
</text></ref><ref id="R42"><text><SENT sid="90718" pm="."><plain>42. GrayAH, WrightJ, BruceL Clinical pharmacy pocket companion. Pharmaceutical Press, 2015. </plain></SENT>
</text></ref></ref-list></SecTag></back></article>
